Media Articles Related to Hexalen (Altretamine)
Study finds biomarker may boost ovarian cancer chemotherapy response
Source: Genetics News From Medical News Today [2015.05.21]
A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.
Chemo Before Surgery May Boost Outcomes for Advanced Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2015.05.20]
Title: Chemo Before Surgery May Boost Outcomes for Advanced Ovarian Cancer
Category: Health News
Created: 5/20/2015 12:00:00 AM
Last Editorial Review: 5/20/2015 12:00:00 AM
Study Sees Improving Survival Odds for Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2015.05.08]
Title: Study Sees Improving Survival Odds for Ovarian Cancer
Category: Health News
Created: 5/7/2015 12:00:00 AM
Last Editorial Review: 5/8/2015 12:00:00 AM
New Method May Detect Ovarian Cancer Earlier
Source: MedicineNet Ovarian Cancer Specialty [2015.05.06]
Title: New Method May Detect Ovarian Cancer Earlier
Category: Health News
Created: 5/6/2015 12:00:00 AM
Last Editorial Review: 5/6/2015 12:00:00 AM
Genes Linked to Breast, Ovarian Cancers Act Differently in Each Woman: Study
Source: MedicineNet Ovarian Cancer Specialty [2015.04.08]
Title: Genes Linked to Breast, Ovarian Cancers Act Differently in Each Woman: Study
Category: Health News
Created: 4/7/2015 12:00:00 AM
Last Editorial Review: 4/8/2015 12:00:00 AM
Published Studies Related to Hexalen (Altretamine)
The bioavailability of three altretamine formulations. [1989.12.15]
The bioavailability of two altretamine preparations was studied in a randomized cross-over design. The two preparations were compared with a third in a parallel design... The in vivo data showed a trend to differences in bioavailability.
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. [2008.12]
PURPOSE: Irofulven (MGI 114, NSC 683863) is a semisynthetic derivative of illudin S, a natural product present in the Omphalotus illudins (Jack O'Lantern) mushroom. This novel agent produces DNA damage, that in contrast to other agents, is predominately ignored by the global genome repair pathway of the nucleotide excision repair (NER)(2) system. The aim of this study was to determine the antitumor activity of irofulven when administered in combination with 44 different DNA damaging agents, whose damage is in general detected and repaired by the genome repair pathway... CONCLUSION: These results indicate that the antitumor activity of irofulven is enhanced when combined with platinum-derived agents, altretamine, and select alkylating agents such as melphalan or chlorambucil. A common factor between these agents appears to be the production of intrastrand DNA crosslinks. The synergistic interaction between irofulven and other agents may stem from the nucleotide excision repair system being selectively overwhelmed at two distinct points in the pathway, resulting in prolonged stalling of transcription forks, and subsequent initiation of apoptosis.
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. [2004.03]
OBJECTIVE: This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy... CONCLUSIONS: Consolidation therapy with oral altretamine was generally well tolerated and associated with prolonged progression-free and overall survival in the Phase II setting.
Oral altretamine used as salvage therapy in recurrent ovarian cancer. [2004.01]
CONCLUSION: Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity.
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. [2003.02]
OBJECTIVE: To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months... CONCLUSION: Altretamine should not be chosen as standard treatment in patients with platinum-resistant recurrent ovarian cancer. However, Altretamine represents a useful alternative in patients who prefer oral treatment or when socioeconomic considerations are an important issue.
Clinical Trials Related to Hexalen (Altretamine)
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors [Recruiting]
This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion
protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to
people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that
promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk
colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice
Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests [Recruiting]
This is a double-blind study with respect to the diluents used, with patients known to be
allergic to the specific allergen tested. Three study sites will be involved, each testing
one allergen (Cat, Mite, Timothy grass pollen). Subjects who are known to be allergic to
the allergen in question will be tested with serial three-fold dilutions to determine the ID
50 and relative extract potency using the method described by Turkeltaub.
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer [Completed]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating
patients with HIV-related cancer.
Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage. [Recruiting]
The aim of this study is to describe acute neurocardiogenic injury after subarachnoid
hemorrhage assessed with cardiac 123I-MIBG scintigraphy and 18F-FDG PET/CT during the first
week and the first six months after SAH.
The study hypothesis is that the evolution of the cardiac disturbances follows the clinical
A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA [Recruiting]
This is a prospective, validation study of a extempore made tracer compared with a
commercial. Studies with tracer have no medical effects but are used for studying human
physiology, in this case pharmacokinetic variables of endogenous albumin distribution and
turnover at different levels of inflammation.
1. Primary Objective:
- Do the extempore made tracer 123-iodine labeled albumin an commercially manufactured
SERALB-125 give identical values of calculated blood plasma volume and capillary
leakage measured as transcapillary escape rate of albumin?
2. Secondary Objective:
- How do three different measures of albumin turnover correlate in volunteers?
- How do the pharmacokinetic parameters of endogenous albumin vary between the three